23andMe Holding Co. operates as a consumer genetics and research company. The company provides a crowdsourced platform for genetic research. Its platform has generated various publications on the genetic underpinnings of a range of diseases, conditions, and traits, as well as enables it in pursuing drug discovery programs rooted in human genetics across various disease areas, including oncology, respiratory, and cardiovascular diseases, as well as other therapeutic areas. The company was founded in 2006 and is based in Sunnyvale, California.
IPO Year:
Exchange: NASDAQ
Website: 23andme.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/29/2022 | $7.00 | Buy | Berenberg |
9/22/2022 | $6.00 | Outperform | Cowen |
2/11/2022 | $14.00 → $11.00 | Outperform | Credit Suisse |
12/20/2021 | $13.00 → $9.00 | Neutral | Citigroup |
11/15/2021 | $12.00 → $13.00 | Buy → Neutral | Citigroup |
11/11/2021 | $13.00 → $14.00 | Outperform | Credit Suisse |
8/17/2021 | $13.00 | Outperform | Credit Suisse |
7/12/2021 | $14.00 | Buy | Citigroup |
4 - 23andMe Holding Co. (0001804591) (Issuer)
4 - 23andMe Holding Co. (0001804591) (Issuer)
4 - 23andMe Holding Co. (0001804591) (Issuer)
4 - 23andMe Holding Co. (0001804591) (Issuer)
4 - 23andMe Holding Co. (0001804591) (Issuer)
4 - 23andMe Holding Co. (0001804591) (Issuer)
4 - 23andMe Holding Co. (0001804591) (Issuer)
4 - 23andMe Holding Co. (0001804591) (Issuer)
4 - 23andMe Holding Co. (0001804591) (Issuer)
4 - 23andMe Holding Co. (0001804591) (Issuer)
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2024 (GLOBE NEWSWIRE) -- The independent directors of the Board of 23andMe Holding Co. (NASDAQ:ME), today sent the following letter to Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, in which the independent directors have provided their resignation from the Board, effective immediately: Dear Anne, We, the independent directors of the 23andMe Board, hereby tender our resignations, effective immediately. After months of work, we have yet to receive from you a fully financed, fully diligenced, actionable proposal that is in the best interests of the non-affiliated shareholders. We believe the Specia
23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and a subset of adenocarcinomas, offering potential indications to assess clinical activity Phase 1 trial ongoing with first patient dosed in March 2024 SUNNYVALE, Calif., Sept. 15, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) ("23andMe"), a leading human genetics and biopharmaceutical company, announced nonclinical data supporting the anti-tumor activity of its first-in-class 23ME-01473 ('1473) antibody targeting the NKG2D ligand ULBP6 at the European Society of Medical Oncolog
23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response Higher tumor expression of CD200 and human genetics correlated with increased clinical benefit, suggesting potential value as patient selection biomarkers Greater response in "cold" tumors suggests opportunity in patients unable to benefit from PD-1/PD-L1 checkpoint inhibitors SUNNYVALE, Calif., Sept. 15, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) ("23andMe"), a leading human genetics and biopharmaceutical company, announced positive preliminary Phase 2 safety and efficacy data from its Phase 1/2a clinical trial covering two n
Preliminary data from renal cancer and TMB-H/MSI-H cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented Analysis of CD200 as an exploratory tissue-based biomarker associated with 23ME-00610 efficacy to be presented Preclinical murine data on 23ME-01473 to be presented; Phase 1/2a dose escalation study ongoing SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced that it will display three poster presentations on 23ME-00610, a first-in-class anti-CD200R1 antibody, and two on 23ME-01473, an anti-ULBP6 monoclonal antibody, at the European Society
SUNNYVALE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (NASDAQ:ME), and a leading telemedicine provider, is now offering Ozempic®, Wegovy® and compounded semaglutide through a weight loss program on its telehealth platform, providing consumers with access to affordable weight management care through a convenient subscription-based model. If prescribed, Lemonaid Health patients will now have access to once-weekly injectable GLP-1 medication offerings through an accessible monthly membership subscription that includes clinician consultations (via video or phone), a GLP-1 prescription (additional cost), ongoing care and support, as we
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, reported its financial results for the first quarter of fiscal year 2025 (FY25), which ended June 30, 2024. Key Results and Recent Developments Reported total revenue of $40 million in the first quarter of fiscal 2025, a decrease of approximately 34% over the same period in the prior year primarily due to lower research revenue after the conclusion of the GSK collaboration exclusivity term in July 2023, as well as lower consumer revenue from decreased PGS kit volumes and telehealth orders.Announcing the launch of a large-scale genetic res
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, today sent the following letter to Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, in response to Ms. Wojcicki's previously disclosed preliminary non-binding indication of interest to acquire all of the outstanding shares of 23andMe not owned by her or her affiliates or any other stockholder that she invites to roll over their shares for cash consideration of $0.40 per share of Class A Common Stock or Class B Common Stock: Dear Anne, We
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, has received a preliminary non-binding indication of interest from Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, to acquire all of the outstanding shares of 23andMe not owned by her or her affiliates or any other stockholder that she invites to roll over their shares for cash consideration of $0.40 per share of Class A Common Stock or Class B Common Stock (the "Proposal"). Ms. Wojcicki announced the Proposal on July 31, 2024 in a Schedule 13D filing with the Securities and Exchange Commi
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the first quarter of fiscal year 2025 (FY2025) after the market closes on Thursday, August 8, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's results and report on business progress. The webcast can be accessed on the day of the event at https://investors.23andme.com/news-events/events-presentations. A webcast replay will be
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy organizations, today announced a new study to help advance research in lung cancer. The focus of the Lung Cancer Genetics Study is to better understand the genetics of people with lung cancer in order to improve detection, risk reduction, and care. While recent developments in tumor genetic testing and targeted therapies have provided hope and years of survival to many lung cancer patients, lung cancer remains the number one cause of cancer deaths in both men and women in the United States. Yet, much rema
The focus of the Lung Cancer Genetics Study is to better understand the genetics of people with lung cancer in order to improve detection, risk reduction, and care. While recent developments in tumor genetic testing and targeted therapies have provided hope and years of survival to many lung cancer patients, lung cancer remains the number one cause of cancer deaths in both men and women in the United States. Yet, much remains unknown about the disease and its causes.
As part of the pilot, 23andMe will offer up to 5,000 23andMe+ Premium and Total Health members the opportunity to receive blood testing through Nightingale's Remote Health Check at no cost to them. The pilot will evaluate customer feedback around blood testing, at-home sample collection, and the utility of the data when coupled with 23andMe's established personal genetics products.
23andMe Holding's (NYSE:ME) short percent of float has fallen 6.06% since its last report. The company recently reported that it has 36.69 million shares sold short, which is 11.79% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.04 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short intere
- Reuters
– 23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit, including one confirmed partial response – 23ME-00610 monotherapy continues to demonstrate acceptable safety and tolerability, and achieves the prespecified targets for maximal pharmacology at 1400 mg dosed Q3W– Tumor CD200 is emerging as a potential biomarker associated with 23ME-00610 monotherapy efficacySOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) ("23andMe"), a leading human genetics and biopharmaceutical company, announced positive preliminary Phase 2 safety and efficacy data from 23ME-00610, a first-in-class anti-CD200R1 antibody, presented at the 2024 Ameri
Gainers OneMedNet (NASDAQ:ONMD) stock moved upwards by 15.6% to $1.7 during Thursday's after-market session. The company's market cap stands at $40.5 million. 23andMe Holding (NASDAQ:ME) shares increased by 11.85% to $0.57. The company's market cap stands at $275.2 million. As per the news, the Q4 earnings report came out today. Biora Therapeutics (NASDAQ:BIOR) stock moved upwards by 10.0% to $0.55. The market value of their outstanding shares is at $19.7 million. Cue Health (NASDAQ:HLTH) shares moved upwards by 9.54% to $0.1. The company's market cap stands at $16.4 million. Accelerate Diagnostics (NASDAQ:AXDX) shares increased by 9.01% to $1.39. The market value of their outstanding s
23andMe Holding (NASDAQ:ME) reported quarterly losses of $(0.43) per share. The company reported quarterly sales of $64.028 million which beat the analyst consensus estimate of $55.822 million by 14.70 percent. This is a 30.69 percent decrease over sales of $92.377 million the same period last year.
SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)
SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)
SC 13G/A - 23andMe Holding Co. (0001804591) (Subject)
SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)
SC 13G/A - 23andMe Holding Co. (0001804591) (Subject)
SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)
SC 13G - 23andMe Holding Co. (0001804591) (Subject)
SC 13G - 23andMe Holding Co. (0001804591) (Subject)
SC 13G - 23andMe Holding Co. (0001804591) (Subject)
SC 13G - 23andMe Holding Co. (0001804591) (Subject)
Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4
SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its therapeutics, research services and consumer groups. Afkhami will be responsible for spearheading and driving a wide range of industry collaborations for the Company. 23andMe Therapeutics has a pipeline of genetically validated discovery and clinical programs, which it intends to advance through collaborations with pharmaceutical companies. Furthermore, 23andMe hopes to help the pharmac
TORONTO, May 24, 2022 /CNW/ - Quarterhill Inc. ("Quarterhill" or "the Company") (TSX:QTRH) (OTCQX:QTRHF) announces that John Karnes has been appointed Chief Financial Officer ("CFO") of the Company effective June 6, 2022. Mr. Karnes will replace Steve Thompson, Wi-LAN Inc.'s CFO, who is currently interim-CFO of Quarterhill. Mr. Karnes is an experienced technology executive with more than 20 years spent in CFO roles within both publicly traded and private equity enterprises. Specifically, he has extensive experience in CFO roles with public companies listed on the NYSE and NASDAQ, including Mariner Energy (NYSE:ME), The Houston Exploration Company (NYSE:THX), CyberCash, Inc. (NASDAQ:CYCH) and
MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail"), a technology-enabled pharmacy company, today announced that Mark Doerr, RPh, has joined the company as chief executive officer ("CEO") and director, effective January 10, 2022. Mr. Doerr succeeds Ed Kilroy, who retired as CEO and from the board of directors and is moving into an advisory role through March 31, 2022. The company also announced changes to its board of directors and reported preliminary fourth quarter and full year 2021 revenue results. Gerard van Hamel Platerink has stepped down as chairperson of the board of directors. Mr. van Hamel Platerink has served on MedAvail's board of directors since June 2012. He is succeeded by c
SUNNYVALE, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) ("23andMe"), a leading consumer genetics and therapeutics company, today announced the appointment of Joseph R. Arron, M.D., Ph.D., as the company's new Chief Scientific Officer. In this role, Dr. Arron will determine and prioritize 23andMe's therapeutic programs and indications, including drug discovery and target validation efforts, and build out a pipeline that yields clinical stage programs. Dr. Arron will report to Kenneth Hillan, Head of Therapeutics at 23andMe. "We are excited to have Joe join as our Chief Scientific Officer, as he brings a proven track record of innovation in drug discover
SUNNYVALE, Calif., Nov. 9, 2021 /PRNewswire/ -- 23andMe Holding Co. (NASDAQ:ME) ("23andMe"), a leading consumer genetics and research company, today announced the appointment of Dr. Sandra Hernández, President & CEO of the California Health Care Foundation ("CHCF"), to its Board of Directors. "Dr. Hernández is a passionate advocate for improving today's healthcare system by enabling anyone, including those in underserved communities, to get access to the care they need," said Anne Wojcicki, CEO, and Co-Founder of 23andMe. "Leveraging her incredible expertise, Dr. Hernández wi
Berenberg initiated coverage of 23andMe with a rating of Buy and set a new price target of $7.00
Cowen initiated coverage of 23andMe with a rating of Outperform and set a new price target of $6.00
Credit Suisse reiterated coverage of 23andMe Holding with a rating of Outperform and set a new price target of $11.00 from $14.00 previously
Citigroup reiterated coverage of 23andMe Holding with a rating of Neutral and set a new price target of $9.00 from $13.00 previously
Citigroup downgraded 23andMe from Buy to Neutral and set a new price target of $13.00 from $12.00 previously
Credit Suisse reiterated coverage of 23andMe Holding with a rating of Outperform and set a new price target of $14.00 from $13.00 previously
Credit Suisse initiated coverage of 23andMe Holding with a rating of Outperform and set a new price target of $13.00
Citigroup initiated coverage of 23andMe with a rating of Buy and set a new price target of $14.00
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, reported its financial results for the first quarter of fiscal year 2025 (FY25), which ended June 30, 2024. Key Results and Recent Developments Reported total revenue of $40 million in the first quarter of fiscal 2025, a decrease of approximately 34% over the same period in the prior year primarily due to lower research revenue after the conclusion of the GSK collaboration exclusivity term in July 2023, as well as lower consumer revenue from decreased PGS kit volumes and telehealth orders.Announcing the launch of a large-scale genetic res
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the first quarter of fiscal year 2025 (FY2025) after the market closes on Thursday, August 8, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's results and report on business progress. The webcast can be accessed on the day of the event at https://investors.23andme.com/news-events/events-presentations. A webcast replay will be
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, reported its financial results for the fourth quarter and full year of fiscal year 2024 (FY24), which ended March 31, 2024. Key Results and Recent Developments On March 28, 2024 the Board of Directors of 23andMe formed a Special Committee comprised of independent directors to review strategic alternatives that may be available to 23andMe to maximize shareholder value. On April 18, 2024 the Company announced it has been made aware that Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, is con
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fourth quarter and full fiscal year 2024 (FY2024) after the market closes on Thursday, May 23, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter and year's financial results and report on business progress. The webcast can be accessed on the day of the event at https://investors.23andme.com/news-events/events-presentations. A w
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024 (FY24), which ended December 31, 2023. Key Results Reported total revenue of $44.7 million in the third quarter of fiscal 2024, compared to $66.9 million in the third quarter of fiscal 2023, a decrease of approximately 33% due to lower research revenue after the conclusion of the GSK collaboration exclusivity term in July 2023 and lower PGS kit volumes.Announced a non-exclusive data license with GSK plc (NYSE:GSK) for novel drug target discovery and other research. U
SOUTH SAN FRANCISCO, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fiscal year 2024 (FY2024) third quarter after the market closes on Wednesday, February 7, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's financial results and report on business progress. The webcast can be accessed on the day of the event at https://investors.23andme.com/news-events/events-presentations. A webcast replay
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second quarter of fiscal year 2024 (FY24), which ended September 30, 2023. Recent Highlights Consumer Increased kit and subscription pricing, seeing better than expected results, helping improve margin profile and highlighting increasing value of product to consumers.Launched 23andMe+ Total Health - 23andMe's most advanced prevention-based health membership. It includes clinical grade exome sequencing, biannual blood biomarker testing and access to clinicians with unique trai
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fiscal year 2024 (FY2024) second quarter after the market closes on Wednesday, November 8, 2023. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's financial results and report on business progress. The webcast can be accessed on the day of the event at https://investors.23andme.com/news-events/events-presentations. A webcast repla
Reaffirmed Full Year Revenue Guidance and Raised Full Year Guidance for Net Loss and Adjusted EBITDA Deficit Webcast at 4:30 pm ET, August 8, 2023 SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmaceutical company, reported its financial results for the first quarter (Q1) of fiscal year 2024 (FY2024), which ended June 30, 2023. 23andMe is the only company with multiple U.S. Food and Drug Administration (FDA) authorizations for over-the-counter genetic health reports. 23andMe also has the largest crowdsourced platform for advanced genetic research, which enables the Company to deliver
SOUTH SAN FRANCISCO, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fiscal year 2024 (FY2024) first quarter after the market closes on Tuesday, August 8, 2023. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's financial results and report on business progress. The webcast can be accessed on the day of the event at https://investors.23andme.com/news-events/events-presentations. A webcast replay wil
8-K - 23andMe Holding Co. (0001804591) (Filer)
10-Q - 23andMe Holding Co. (0001804591) (Filer)
8-K - 23andMe Holding Co. (0001804591) (Filer)
8-K - 23andMe Holding Co. (0001804591) (Filer)
8-K - 23andMe Holding Co. (0001804591) (Filer)
ARS - 23andMe Holding Co. (0001804591) (Filer)
DEFA14A - 23andMe Holding Co. (0001804591) (Filer)
DEF 14A - 23andMe Holding Co. (0001804591) (Filer)
PRE 14A - 23andMe Holding Co. (0001804591) (Filer)
144 - 23andMe Holding Co. (0001804591) (Subject)